Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Simple exercise program may shield breast cancer patients from nerve damage

NCT ID NCT04583124

First seen Nov 18, 2025 · Last updated Jun 22, 2026 · Updated 25 times

Summary

This study tested whether a program of therapeutic exercise and relaxation techniques (called ATENTO) could prevent nerve damage (neurotoxicity) in women newly diagnosed with breast cancer. 42 women were split into two groups: one started the program before cancer treatment, the other during treatment. Researchers measured quality of life and cognitive function to see which timing worked best.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST NEOPLASM are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • University of Granada

    Granada, 18016, Spain

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

therapeutic exercise and vagal activation techniques

What this could lead to

If it works, this could point toward a simple, drug-free way to prevent nerve damage from cancer treatment, improving quality of life for breast cancer patients.

What could go wrong

This is a very small, early study with only 42 participants, so results may not apply to everyone. The intervention is not a treatment for cancer itself, only for side effects.

Conditions

The condition(s) this trial relates to.

breast neoplasm toxic encephalopathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.